The U.S. Food and Drug Administration has approved Indianapolis-based Eli Lilly's new treatment for moderate to severe eczema ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...

INDIANAPOLIS–The U.S. Food and Drug Administration has approved Eli Lilly’s new treatment for moderate to severe eczema. It’s ...

The move to self-administration with a syringe and needle, just like how insulin is often taken for diabetes, means a whole ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Groundbreaking for the Limerick site took place in March 2023, with production expected to commence in 2026. The September 13, 2024 announcement of the additional investment signifies Eli Lilly's ...

Eli Lilly said the Food and Drug Administration approved its treatment for moderate-to-severe eczema that isn't well controlled despite treatment with topical prescription therapies.

The Indiana Budget Committee last month approved $50 million in funding for bond financing of a water pipeline from ...